The Filing Desk

Dianthus Therapeutics

DNTH · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

DNTH · Last close · November 13, 2026
$91.81
Value Dianthus Therapeutics yourself

Dianthus Therapeutics' revenue fell 67.3% to $2 million in fiscal 2025. Its operating margin was −8,739.3%, down from −1,633.7% a year earlier. Free cash flow was −$129 million. The diluted share count rose 15.9%.

Dianthus Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 9, 2026 · 0001690585-26-000006 Updated
Revenue
$2M
67.3%
Operating margin
−8,739.3%
7105.6 pts
Net income
−$162M
 
Free cash flow
−$129M
 
Return on equity
−38.4%
5.8 pts
Market cap
$5.3B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Dianthus Therapeutics does

Dianthus Therapeutics is a clinical-stage biotechnology company, which means it is testing its medicines in people and has none approved for sale. It is working on treatments for severe autoimmune diseases, in which the immune system attacks the body's own tissue.

Its lead candidate, claseprubart, is an antibody that blocks one active part of the complement system, a branch of the immune system that can cause damage in these diseases. The company designed it to be given less often, as an injection patients can give themselves with a pre-filled pen. Dianthus believes it could be used for many complement-driven diseases.

Its second candidate, DNTH212, is a fusion protein that targets two immune pathways at once, one involving interferon production and one involving B cells. It is also designed for self-injection.

Dianthus has a limited operating history and has not finished any late-stage clinical trial. It says it will need substantial new capital to fund its work.

Its biggest risks, as it describes them

  • It has no approved products, a limited operating history and has not finished a late-stage clinical trial.
  • It will need substantial additional capital, and may not be able to raise it on acceptable terms.
  • It has lost money since it began and expects more losses for the foreseeable future.
  • It depends heavily on the success of one candidate, claseprubart, and its planned trials.
  • Its approach to finding and developing medicines is unproven, and competitors are working on the same diseases.
From Dianthus Therapeutics's annual report on Form 10-K, filed March 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Dianthus Therapeutics lost money in fiscal 2025: a net loss of $162 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments177761312250
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio16.6x10.0x18.4x15.2x13.3x
Quick ratio16.6x10.0x18.4x15.2x13.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Dianthus Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Dianthus Therapeutics says to expect

  • Cash position: expected runwayApproximately $1.2 billion of cash, cash equivalents and investments as of September 30, 2026, is projected to provide runway into 2030.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Dianthus Therapeutics shares on the open market, and 8 insiders sold $79.2 million, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 12, 2026Ryan SavitzEVP, CFO & CboSold plan17,724$90.56$1.6 millionForm 4
Nov 11, 2026Ryan SavitzEVP, CFO & CboSold plan3,044$90.03$274,051Form 4
Nov 10, 2026Ryan SavitzEVP, CFO & CboSold plan2,561$90.14$230,849Form 4
Nov 9, 2026Ryan SavitzEVP, CFO & CboSold plan100,713$90.54$9.1 millionForm 4
Sep 17, 2026Edward CarrChief Accounting OfficerSold plan20,000$101.38$2.0 millionForm 4
Sep 1, 2026Simrat RandhawaEVP, Head of R&DSold plan23,124$106.41$2.5 millionForm 4
Aug 19, 2026Simon ReadDirectorSold plan2,778$117.55$326,554Form 4
Aug 10, 2026Adam M VenessSVP, General Counsel and Sec.Sold plan16,167$110.38$1.8 millionForm 4
Aug 10, 2026Anne McGeorgeDirectorSold plan7,750$109.01$844,822Form 4
Aug 10, 2026Simon ReadDirectorSold plan2,777$109.55$304,232Form 4
Aug 7, 2026Marino GarciaCEO and President, DirectorSold plan166,000$108.11$17.9 millionForm 4
Aug 7, 2026Adam M VenessSVP, General Counsel and Sec.Sold plan3,833$110.70$424,319Form 4
The latest 12 of 25 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40—−1,134.9%−6,416.7%
Altman Z''19.5418.4414.17
Accruals ratio−5.1%−2.5%−7.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—PassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Dianthus Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Dianthus TherapeuticsFY25−67.3%−8,739.3%−6,349.4%———
ImmunomeFY25−23.2%−3,228.8%−2,890.1%———Compare
Ovid TherapeuticsFY251,181.3%−585.2%−528.6%———Compare
Xenon PharmaceuticalsFY25—−4,974.3%−3,732.2%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000———362
Revenue growth————————120.6%−67.3%
Gross profit——————————
Research and development62841595147293383146
Operating income−9−36−60−83−79−75−30−48−102−178
Net income−9−36−58−77−75−71−28−44−85−162
Diluted EPS (US$)−65.15−19.12−3.13−2.07−1.71−1.29−32.57−8.45−2.55−4.20
Diluted shares (millions)0218374455153339
Cash flow
Cash from operations−6−22−42−57−64−60−29−37−78−129
Capital expenditure0283010000
Free cash flow−7−24−50−60−64−61−29−37−78−129
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1211101010231323
Balance sheet at fiscal year end
Cash and short-term investments451143146149177761312250
Debt incl. finance leases——————————
Total assets—5415716216219083179374531
Total liabilities—41220181710102238
Shareholders' equity−9−42146141144−17−44169352493
Margins and ratios
Gross margin——————————
Operating margin———————−1,704.7%−1,633.7%−8,739.3%
Net margin———————−1,541.2%−1,362.8%−7,973.3%
Free cash flow margin———————−1,308.2%−1,255.6%−6,349.4%
Rule of 40 (growth + FCF margin)————————−1,134.9%−6,416.7%
Return on capital——————————
Return on equity——−111.1%−53.5%−52.6%−112.3%—−70.0%−32.6%−38.4%
Return on assets——−54.3%−48.2%−46.4%−40.5%−20.9%−33.2%−30.7%−35.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Dianthus Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Dianthus Therapeutics.